AGM
HUMA icon

Alpine Global Management’s Humacyte HUMA Stock Holding History

Alpine Global Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26,744
Closed -$128K – 284
2024
Q2 		$128K Buy
+26,744
New +$139K 0.02% 374
2021
Q3 		– Sell
-209,743
Closed -$2.14M – 321
2021
Q2 		$2.14M Sell
209,743
-311,412
-60% -$3.21M 0.29% 74
2021
Q1 		$5.64M Buy
+521,155
New +$5.69M 0.54% 39

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alpine Global Management's HUMA Position: Q3 2024 in Review

Alpine Global Management sold out of Humacyte (HUMA) in Q3 2024, closing a stake of 26,744 shares — an estimated $128K sold.

Alpine Global Management first reported a position in HUMA in Q1 2021 and held it in 3 quarters. The position peaked at $5.64M in Q1 2021. 143 funds tracked by Wall St. Rank hold HUMA as of Q3 2024.

  • Alpine Global Management reported no remaining Humacyte position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 26,744 Humacyte shares in Q3 2024, an estimated $128K.
  • Alpine Global Management first reported a position in Humacyte in Q1 2021 and held it in 3 quarters.
  • Alpine Global Management's Humacyte position peaked at $5.64M in Q1 2021.
  • 143 funds tracked by Wall St. Rank held Humacyte as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.